학술논문
A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age
Document Type
Article
Author
Source
In: PLoS ONE . (PLoS ONE, August 2023, 18(8 August))
Subject
Language
English
ISSN
19326203